Merck’s Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, Met Primary Endpoint in the Pivotal Phase 2b/3 BRUNELLO Study of Adults with Diabetic Macular Edema

Merck announced topline results from BRUNELLO, a pivotal Phase 2b/3 trial of investigational remigromig (MK-3000) in adults with diabetic macular edema. The therapy is a potentially first-in-class tetravalent, tri-specific antibody designed to activate the Wnt pathway, and BRUNELLO is the first of two Phase 2b/3 studies evaluating its safety and efficacy. The provided article excerpt does not disclose efficacy, safety, or statistical results.

Analysis

The relevant valuation question is not whether BRUNELLO was labeled positive, but whether remigromig demonstrates a clinically meaningful durability or vision-gain advantage versus established anti-VEGF/Ang-2 regimens. With the efficacy tables, dosing interval, discontinuation rate, and ocular-inflammation data absent, this is not yet a model-changing event for MRK. The program’s strategic value is as a potential non-oncology growth pillar ahead of Keytruda LOE, but DME contribution would likely be a 2029+ earnings issue even under a strong read-through.

If remigromig can maintain non-inferior BCVA gains at materially fewer injections, the principal competitive pressure falls on REGN’s Eylea franchise and RHHBY’s Vabysmo, where retinal-treatment burden is central to product differentiation and payer contracting. A merely non-inferior outcome at comparable injection frequency would have limited commercial value: retina specialists have substantial switching friction, while incumbent products have entrenched reimbursement pathways and real-world safety familiarity. ABBV is a secondary beneficiary of a more competitive retinal market only insofar as it raises the value of its own ophthalmology pipeline and creates partnering/M&A scarcity.

Consensus may over-credit the platform label before durability is proven. Wnt-pathway activation could offer retinal-repair differentiation, but it also raises the bar on long-term ocular safety, especially inflammation, vascular leakage, and any proliferative-retinopathy signal; those risks can emerge only with longer follow-up. Near term, MRK’s share reaction should be constrained unless management provides enough detail to support probability-of-success and peak-sales revisions; the second pivotal trial, comparative dosing burden, and regulatory-endpoint alignment are the 1-3 month catalysts.

Key Decisions for Investors

• Do not add directional MRK exposure solely on this release. Set an event-driven alert for the full BRUNELLO dataset: consider a tactical MRK long only if vision outcomes are non-inferior or better versus control, at least 30-50% fewer annual injections, and no meaningful ocular-safety imbalance; those conditions could justify a $1-3B risk-adjusted peak-sales uplift.
• Maintain REGN as the cleaner relative-value hedge against a strong remigromig dataset: on detailed evidence of materially longer dosing intervals, initiate a 3-6 month long MRK / short REGN pair in equal beta-adjusted dollars. Target 8-12% relative return; exit if durability is comparable to existing therapy or if MRK declines to disclose control-arm and injection-frequency data.
• Avoid shorting RHHBY on preliminary implications. Vabysmo’s global franchise and established durability profile make displacement a multi-year process; reassess only after the second pivotal trial confirms reproducibility and MRK discloses a credible commercial-launch timeline.
• For existing MRK holders, use any sharp data-light rally to reduce rather than chase: absent disclosed effect size and safety follow-up, upside is narrative-driven while a later efficacy, durability, or inflammation disclosure could reverse the move quickly.